Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Oct;106(10):802-812.
doi: 10.1007/s00392-017-1122-1. Epub 2017 May 24.

Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction

Yuya Matsue  1   2 , Jozine M Ter Maaten  3 , Makoto Suzuki  4 , Sho Torii  5 , Satoshi Yamaguchi  6 , Seiji Fukamizu  7 , Yuichi Ono  8 , Hiroyuki Fujii  9 , Takeshi Kitai  10 , Toshihiko Nishioka  11 , Kaoru Sugi  12 , Yuko Onishi  13 , Makoto Noda  14 , Nobuyuki Kagiyama  15 , Yasuhiro Satoh  16 , Kazuki Yoshida  17 , Peter van der Meer  3 , Kevin Damman  3 , Adriaan A Voors  3 , Steven R Goldsmith  18
Affiliations
Randomized Controlled Trial

Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction

Yuya Matsue et al. Clin Res Cardiol. 2017 Oct.

Abstract

Background: Poor response to diuretics is associated with worse prognosis in patients with acute heart failure (AHF). We hypothesized that treatment with tolvaptan improves diuretic response in patients with AHF.

Methods: We performed a secondary analysis of the AQUAMARINE open-label randomized study in which a total of 217 AHF patients with renal impairment (eGFR < 60 mL/min/1.73 m2) were randomized to either tolvaptan or conventional treatment. We evaluated diuretic response to 40 mg furosemide or its equivalent based on two different parameters: change in body weight and net fluid loss within 48 h.

Results: The mean time from patient presentation to randomization was 2.9 h. Patients with a better diuretic response showed greater relief of dyspnea and less worsening of renal function. Tolvaptan patients showed a significantly better diuretic response measured by diuretic response based both body weight [-1.16 (IQR -3.00 to -0.57) kg/40 mg vs. -0.51 (IQR -1.13 to -0.20) kg/40 mg; P < 0.001] and net fluid loss [2125.0 (IQR 1370.0-3856.3) mL/40 mg vs. 1296.3 (IQR 725.2-1726.5) mL/40 mg; P < 0.001]. Higher diastolic blood pressure and use of tolvaptan were independent predictors of a better diuretic response.

Conclusions: Better diuretic response was associated with greater dyspnea relief and less WRF. Early treatment with tolvaptan significantly improved diuretic response in AHF patients with renal dysfunction.

Keywords: Acute heart failure; Diuretics; Dyspnea relief; Worsening renal function.

PubMed Disclaimer

Conflict of interest statement

Funding

AQUAMARINE study was funded by Japan Heart Foundation Multicenter Study Grant.

Conflict of interest

Dr.Yuya Matsue is supported by JSPS (Japan Society for the Promortion of Science) Overseas Research Fellowship, and received a honorarium from Otsuka Pharmaceutical Co. Dr. Makoto Suzuki received lectures honoraria from Bayer, Otsuka Pharmaceutical Co., Biotronik Japan Co., Daiichi-Snakyo, Medtronic Japan Co., Ltd., St. Jude Medical Japan, and Fukuda Denshi. Dr. Yuichi ono received lectures honoraria from Medtronic Japan Co., Ltd. Dr. Kazuki Yoshida receives tuition support jointly from the Japan Student Services Organization and Harvard T. H. Chan School of Public Health (partially supported by training Grants from Pfizer, Takeda, Bayer, and PhRMA). Dr. Kaoru Sugi received scholarship fund from Daiichi-Sankyo Pharmaceutical and lectures honoraria from Bayer. Dr. Steven R. Goldsmith received consulting fees, speaking fees, and research support from Otsuka USA and Otsuka-Japan. The other authors have nothing to disclose related to this paper.

Figures

Fig. 1
Fig. 1
Diuretic response in patients with acute heart failure according to treatment with tolvaptan. Measurements compared were a change in body weight and b net fluid loss
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adams KF, Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP, ASA Committee Investigators Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE) Am Heart J. 2005;149:209–216. doi: 10.1016/j.ahj.2004.08.005. - DOI - PubMed
    1. Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JG, Anker SD, Gheorghiade M, Fiuzat M, Rossignol P, Zannad F, Pitt B, O’Connor C, Felker GM. Decongestion in acute heart failure. Eur J Heart Fail. 2014;16:471–482. doi: 10.1002/ejhf.74. - DOI - PMC - PubMed
    1. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123–1133. doi: 10.1016/j.jacc.2013.11.053. - DOI - PubMed
    1. Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014;35:1284–1293. doi: 10.1093/eurheartj/ehu065. - DOI - PubMed
    1. ter Maaten JM, Dunning AM, Valente MA, Damman K, Ezekowitz JA, Califf RM, Starling RC, van der Meer P, O’Connor CM, Schulte PJ, Testani JM, Hernandez AF, Tang WH, Voors AA. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am Heart J. 2015;170:313–321. doi: 10.1016/j.ahj.2015.05.003. - DOI - PubMed

Publication types

MeSH terms